Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial

Clin Infect Dis. 2023 Aug 22;77(4):560-564. doi: 10.1093/cid/ciad209.

Abstract

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.

Keywords: SARS-CoV-2; vaccine; variant.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19* / prevention & control
  • Humans
  • SARS-CoV-2 / genetics
  • Vaccines, Combined

Substances

  • Antibodies, Neutralizing
  • Vaccines, Combined
  • Antibodies, Viral

Supplementary concepts

  • SARS-CoV-2 variants